Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Illumina Launches AI-Driven BioInsight Division for Multi-Omic Drug Discovery

Illumina, a leading provider of DNA sequencing technology, has announced the launch of BioInsight, a new informatics and artificial intelligence (AI) software business aimed at revolutionizing drug discovery through multi-omic data analysis. This strategic move positions Illumina at the forefront of the rapidly evolving intersection between genomics and AI-driven drug development.

NoahAI News10/2/2025

FDA Setback for Rare Pediatric Disease Treatment: Manufacturing Issues Halt Approval

The pharmaceutical industry faced a significant setback as the U.S. Food and Drug Administration (FDA) issued a complete response letter for CUTX-101, a promising treatment for the rare and often fatal Menkes disease. The decision, centered on manufacturing concerns, has delayed hopes for the first approved therapy for this devastating pediatric condition.

NoahAI News10/2/2025

Boston Scientific Unveils Plans for Next-Generation Watchman Device, Targets Market Expansion

Boston Scientific has announced its plans to develop a new version of its Watchman device, aiming to launch the next-generation system in late 2027 or early 2028. The company also revealed strategies to expand the market for its left atrial appendage closure technology, including potential label expansions and increased use in concomitant procedures.

NoahAI News10/2/2025

Pharmaceutical Giants Join Forces in AI-Driven Drug Discovery Initiative

In a groundbreaking move that signals a new era of collaboration in the pharmaceutical industry, several major players have announced their participation in a cutting-edge artificial intelligence project aimed at revolutionizing drug discovery. The Federated OpenFold3 Initiative, launched earlier this year, has now expanded to include Astex Pharmaceuticals, Bristol Myers Squibb (BMS), and Takeda, joining founding members AbbVie and Johnson & Johnson.

NoahAI News10/2/2025

Assort Health Secures $102M in Funding to Revolutionize Healthcare Call Centers with Voice AI

Assort Health, a pioneering voice AI startup, has successfully raised $76 million in a Series B funding round, bringing its total funding to an impressive $102 million in just four months. The company's innovative platform aims to transform healthcare call centers by deploying specialty-specific voice AI agents across various medical fields.

NoahAI News10/2/2025

Takeda Exits Cell Therapy Arena in Strategic Shift, Joining Industry Trend

Takeda Pharmaceutical Company has announced its withdrawal from the cell therapy field as part of a strategic portfolio reprioritization, marking a significant shift in the company's focus and aligning with a broader industry trend away from this modality.

NoahAI News10/2/2025

Halozyme Acquires Elektrofi in $900M Deal, Expanding Subcutaneous Drug Delivery Capabilities

Halozyme Therapeutics has announced a significant acquisition in the subcutaneous drug delivery space, agreeing to purchase Elektrofi for up to $900 million. This strategic move combines two leaders in the field and is set to reshape the landscape of at-home drug administration.

NoahAI News10/2/2025

Pharmaceutical Industry Roundup: M&A Surge, Leadership Changes, and Breakthrough Therapies

In a week marked by significant developments across the pharmaceutical landscape, industry giants made strategic moves while breakthrough therapies offered new hope for patients. From multi-billion dollar acquisitions to groundbreaking clinical results, the sector continues to evolve at a rapid pace.

NoahAI News10/1/2025

Pharmaceutical Industry Update: FDA Approval, Acquisitions, and Clinical Trial Results

The U.S. Food and Drug Administration (FDA) has approved Novartis' Rhapsido (remibrutinib) for the treatment of chronic spontaneous urticaria, a form of persistent hives. This approval marks Rhapsido as the first oral targeted therapy for this condition. The drug belongs to a newer class of BTK inhibitors designed to treat autoimmune diseases rather than cancer.

NoahAI News10/1/2025

Irish Biotech Aerska Launches with $21M to Develop Brain-Targeted RNA Therapies

Aerska, a newly formed biotech company headquartered in Dublin with research operations in London, has emerged onto the pharmaceutical scene with a $21 million seed funding round. The company's mission is to revolutionize the delivery of genetic medicines to the brain, focusing initially on Alzheimer's and Parkinson's diseases.

NoahAI News10/1/2025

AbbVie Expands U.S. Operations with $70M Investment in Massachusetts Facility

AbbVie, the global biopharmaceutical company, has initiated a significant expansion of its U.S. operations, starting with a $70 million investment in its Worcester, Massachusetts bioresearch center. This move is part of a broader $10 billion investment strategy aimed at bolstering the company's domestic presence through 2035.

NoahAI News10/1/2025

Q3 2025 Sees Surge in High-Value Biopharma Acquisitions

The third quarter of 2025 has witnessed a significant uptick in high-value acquisitions within the biopharmaceutical industry, signaling a potential shift towards more substantial dealmaking. While Johnson & Johnson's $14.6 billion acquisition of Intra-Cellular in January remains the largest deal of the year, the past four months have seen a flurry of multi-billion dollar transactions reshaping the industry landscape.

NoahAI News10/1/2025

«1...56 57 58...67 »